Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations

Toshiyuki Miyata; Yumiko Uchida; Toshiyuki Ohta; Kohtaro Urayama; Yoko Yoshida; Yoshihiro Fujimura

doi:10.1160/TH15-01-0007

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 114(04): 862-863
DOI: 10.1160/TH15-01-0007

Letters to the Editor

Schattauer GmbH

Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations

Toshiyuki Miyata

¹Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan

,

Yumiko Uchida

¹Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan

,

Toshiyuki Ohta

²Department of Pediatric Nephrology, Hiroshima Prefectural Hospital, Hiroshima, Japan

,

Kohtaro Urayama

²Department of Pediatric Nephrology, Hiroshima Prefectural Hospital, Hiroshima, Japan

,

Yoko Yoshida

³Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan

,

Yoshihiro Fujimura

³Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan

› Author Affiliations

Abstract

Full Text

References

References
1 Lemaire M, Fremeaux-Bacchi V, Schaefer F. et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531-536.
2 Sanchez Chinchilla D, Pinto S, Hoppe B. et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014; 9: 1611-1619.
3 Ozaltin F, Li B, Rauhauser A. et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013; 24: 377-384.
4 Westland R, Bodria M, Carrea A. et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014; 25: 1408-1414.
5 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 654-666.
6 Bruneau S, Neel M, Roumenina LT. et al. Loss of DGK induces endothelial cell activation and death independently of complement activation. Blood 2015; 125: 1038-1046.
7 Fujimura Y, Matsumoto M, Isonishi A. et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl. 01) 283-301.
8 Fan X, Yoshida Y, Honda S. et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 2013; 54: 238-246.
9 Matsumoto T, Fan X, Ishikawa E. et al. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol 2014; 100: 437-442.
10 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081.
11 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging mis-sense mutations. Nat Methods 2010; 7: 248-249.
12 Ohta T, Urayama K, Tada Y. et al. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 2015; 30: 603-608.